Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

ZhenHeng Wei1, ChuXin Chen2, BoWen Li1, YongYue Li3 and Hong Gu4*

1 Inner Mongolia Medical University, Hohhot, China, 2 Peking Union Medical College Hospital, Beijing, China, 3 Inner Mongolia Medical University, Rehabilitation Department of Baotou Steel Hospital, Baotou, China, 4 Inner Mongolia Baotou Steel Hospital, The Third Clinical Medical College of Inner Mongolia Medical University, Baotou, China

Objective: The androgen receptor-targeting drugs abiraterone acetate and enzalutamide have shown positive results as treatments for metastatic castration-resistant prostate cancer (mCRPC). Therefore, a meta-analysis was conducted to compare the efficacy and safety of abiraterone acetate and enzalutamide in patients with mCRPC.

Methods: We retrieved relevant articles from PubMed, Cochrane, and EMBASE published before December 31, 2020. Eleven articles were initially selected, and four phase III, double-blind, randomized controlled trials of abiraterone acetate and enzalutamide that involved 5199 patients with mCRPC were included. The end points were time to prostate-specific antigen progression (TTPP), according to the prostate-specific antigen working group criteria; overall survival (OS); and radiographic progression-free survival (rPFS).

Results: Four randomized, controlled clinical trials involving 5199 patients were included in this study. The results of the meta-analysis showed that compared with placebo alone, abiraterone significantly improved OS (HR=0.69, 95% CI: 0.60-0.8, P<0.00001), rPFS (HR=0.64, 95% CI: 0.57-0.71, P<0.00001), and TTPP (HR=0.52, 95% CI: 0.45-0.59, P<0.00001) in patients with mCRPC. Compared with placebo, enzalutamide significantly improved OS (HR=0.67, 95% CI: 0.59-0.75, P<0.00001), rPFS (HR=0.33, 95% CI: 0.29-0.37, P<0.00001), and TTPP (HR=0.19, 95% CI: 0.17-0.22, P<0.00001). An indirect comparison was performed to compare the efficacy of abiraterone and enzalutamide. The results showed that there was no significant difference between abiraterone and enzalutamide with regard to improving the OS of patients with mCRPC (HR=1.03, 95% CI: 0.854-1.242). Enzalutamide was superior to abiraterone with regard to improving rPFS in patients with mCRPC (HR=0.516, 95% CI: 0.438-0.608). With regard to improving
INTRODUCTION
Prostate cancer became the leading cause of new cancer cases in the United States and the second leading cause of all cancer-related deaths in 2020, according to Cancer Statistics (1). Advanced prostate cancer has a poor prognosis and is difficult to treat. It can develop into castration-resistant prostate cancer (CRPC) within (1 to 2) years and readily progresses to metastatic CRPC (mCRPC) (2). In recent years, advances in therapeutic drugs have changed the treatment philosophy and strategies for this stage of the disease, although high-level evidence is still lacking. In addition, there are still controversies about how to rationally select and use different drugs to improve the overall treatment efficacy (3–7).

Abiraterone acetate is an enzyme inhibitor of CPY17 that inhibits the residual synthesis of androgen after androgen deprivation therapy and can be used for the treatment of mCRPC in patients who have previously received chemotherapy (8, 9). Enzalutamide (MDV3100), an oral drug targeting the androgen receptor signalling pathway, can competitively inhibit androgen receptor binding. Compared with antiandrogen drugs, such as bicalutamide, previously used in clinical therapy, enzalutamide has a 5- to 8-fold greater affinity for the androgen receptor (10, 11). When used for the treatment of advanced or metastatic hormone-sensitive prostate cancer, both abiraterone acetate and enzalutamide have been shown to reduce mortality and improve overall survival (OS) (12–14). It is necessary to maximize the efficacy of drug therapy for mCRPC and improve the OS of patients (6, 15, 16). Therefore, we conducted a meta-analysis to evaluate the efficacy and safety of these two drugs in patients with mCRPC.

MATERIALS AND METHODS
We registered the protocol for this systematic review with PROSPERO (CRD42021226808). This report complies with the PRISMA meta-analysis extension statement. The trials covered in this article were registered on internationally recognized clinical trial registries, such as the North American Clinical Trial Registry (www.clinicaltrials.gov). In addition, only clinical data of patients are collected in this paper, without intervention in the treatment plan of patients, which will not bring physiological risks to patients, so there is no need for ethical review.

Search Strategy
We retrieved relevant studies from PubMed, Cochrane Library, EMBASE, and ClinicalTrials.gov from the date of database inception to December 31, 2020. MeSH terms and keywords such as “prostate cancer,” “abiraterone,” “enzalutamide,” “clinical trials as topic” and relevant variants were used. For example, the following search terms were used in PubMed: ((((((“Abiraterone Acetate”[Mesh]) OR (17-(3-pyridyl)-5,16-androstadien-3-beta-acetate)) OR (Zytiga)) (CB 7630)) OR (CB-7630)) OR (CB7630)) OR (((“Enzalutamide” OR (MDV3100)) OR (MDV-3100)) OR (MDV-3100)) OR (enzalutamide))) AND (((clinical[tiab] AND trial[tiab]) OR “clinical trials as topic”[mesh]) OR “clinical trial”[pt] OR random*[tiab] OR “random allocation”[mesh]) AND ((((((“Prostatic Neoplasms”[Mesh]) OR (Prostate Neoplasms)) OR (Neoplasms, Prostate)) OR (Neoplasm, Prostate)) OR (Prostate Neoplasm)) OR (Neoplasms, Prostatic)) OR (Prostatic Neoplasm)) OR (Prostatic Cancer)) OR (Cancer, Prostate)) OR (Cancers, Prostate)) OR (Prostate Cancers) OR (Cancer of the Prostate) OR (Prostatic Cancer)) OR (Cancers, Prostatic)) OR (Prostatic Cancers) OR (Cancer of Prostate)).

Study Selection
We included phase III, randomized, double-blind, placebo-controlled clinical trials of the use of abiraterone or enzalutamide for the treatment of mCRPC. Nonrandomized controlled studies, studies with poor experimental designs, studies with inconsistent outcome indicators, reviews, systematic reviews, case reports, studies with median estimates
reported without confidence intervals or boundary values, and studies with no usable clinical results were excluded.

**Data Extraction**

The literature search and screening process was conducted by two investigators independently in accordance with the established inclusion and exclusion criteria. Any differences were resolved by the other investigator. The following data were extracted: year of publication, number of subjects, duration of the intervention, and main outcome indicators. If necessary, the authors were emailed to obtain data on indicators not reported in the study.

**Outcomes**

The primary outcome was OS, and the secondary outcomes were radiographic progression-free survival (rPFS), time to prostate-specific antigen development (TTPP) and serious adverse events (sAEs). OS was defined as the time from the date of randomization to the date of death from any cause. rPFS was defined as the time from randomization to the earliest objective evidence of radiographic progression or death due to any cause. TTPP was defined as the time from randomization to the occurrence of the first bone-related event. An adverse event that results in death is life-threatening, requires inpatient hospitalization or extends a current hospital stay, the results in an ongoing or significant incapacity, interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered serious adverse events if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above.

**Quality Assessment**

The Cochrane risk of bias assessment tool was used, which addresses random sequence generation, allocation concealment, blinding methods (double blind, triple blind), the integrity of outcome data, the selective reporting of study results, and other sources of bias. Quality assessments were performed, and each indicator was assessed as a “low risk of bias”, “high risk of bias” or “unclear”. The following types of bias were considered: selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias.

**Statistical Analysis**

RevMan 5.3 and Indirect Treatment Comparison (ITC) software were used in this meta-analysis to perform indirect comparisons of the use of abiraterone and enzalutamide for the treatment of mCRPC. The hazard ratio (HR) was used as the efficacy effect estimate, and the 95% confidence interval (CI) was calculated. The studies that reported the HR specified whether it was obtained through the Parmar and Tierney method, p-value estimation or survival curve analysis.

The Cochrane Q test was used to assess the heterogeneity of the included studies (the significance level was α=0.1). The magnitude of the heterogeneity was determined quantitatively. If the P value of the Q test was > 0.1 and I² was < 50%, it suggested that there was limited heterogeneity, and a fixed-effect model was used for the meta-analysis. If the P value of the Q test was ≤0.1 or I² was > 50%, sensitivity analyses or subgroup analyses were needed to explore the source of heterogeneity. After removing the influence of heterogeneity, a fixed-effect model was used for the meta-analysis. The significance level for the meta-analysis was set at α=0.05.

**RESULTS**

**Literature Search**

The results of the search and screening process are shown in Figure 1 in the form of a flow diagram. A total of 1,417 papers were initially retrieved from the electronic databases, and 15 papers were obtained by other methods. A total of 413 duplicate articles were excluded, and 933 were excluded based on their titles and abstracts. Twenty-six articles were read in full, and 4 clinical trials were selected from the remaining 86 articles.

The study included 4 clinical trials (7, 17–19), all of which were published in English and administered a placebo to the control group. All were phase III, double-blind, randomized controlled trials. Each trial included participants from multiple countries and regions. The racial and regional bias in each experiment was smaller, which will not affect the results and conclusions. Abiraterone was used for the treatment of mCRPC in 2 clinical trials (2283 patients), and enzalutamide was used in 2 clinical trials (2916 patients). Table 1 summarizes the characteristics of the included studies and the key baseline patient characteristics. The results from the 4 clinical trials were reported as OS, rPFS, TTPP and sAE. Refer to Table 2 for details.

**Quality of the Included Studies**

The risk of bias was evaluated in the four included clinical trials. All four trials were conducted with blinding of the participants, investigators, and outcome assessors. Data for each of the major outcome indicators were reported. Although random assignment was performed, the methods were not described in detail. The results were visualized with RevMan 5.3, as shown in Figures 2, 3.

**Overall Survival**

There were 2 clinical trials comparing the effect of abiraterone with that of a placebo on the OS of 2283 mCRPC patients. Two clinical trials compared the effect of enzalutamide with that of a placebo on the OS of 2283 mCRPC patients. The test of heterogeneity indicated that there was limited heterogeneity between the studies (I² = 4%, P=0.31; I² = 0%, P=0.36), and the fixed-effect model was used for the meta-analysis. The results showed that abiraterone and enzalutamide had significant advantages over placebo with regard to the OS of mCRPC patients (HR=0.69, 95% CI: 0.60-0.80; HR=0.67, 95% CI: 0.59-0.75; Z=5.01, P < 0.00001; Z=6.54, P < 0.00001) (Figure 4). Further indirect comparisons based on different treatment regimens showed no difference between abiraterone and enzalutamide (HR=1.03, 95% CI: 0.854 – 1.242) with regard to OS in mCRPC patients.
FIGURE 1 | Flowchart for the systematic review process and data acquisition.

TABLE 1 | Characteristics of the eligible studies.

| Study          | Years   | NCT Number | Phase | Line | Masking | OS follow-up | Patients | Treatment (N)                  | Control (N)                  | Median Age (SD) | region       |
|----------------|---------|-------------|-------|------|---------|--------------|----------|--------------------------------|---------------------------|-----------------|--------------|
| Karim Fazzi    | 2008-2014| 00638890    | 3     | 2    | Quadruple | Up to 60 months | 1187     | abiraterone + prednisone (797) | prednisone + placebo (390) | 69 (8.46)       | multicenter  |
| Kurtr Miller   | 2009-2018| 00887198    | 3     | 1    | Quadruple | Up to 61 months | 1088     | abiraterone + prednisone (546) | prednisone + placebo (542) | 70.3 (8.76)     | multicenter  |
| Andrew J       | 2009-2018| 00974311    | 3     | 2    | Triple   | Up to 101 months | 1199     | Enzalutamide (800)             | placebo (399)           | 68.7 (8.11)     | multicenter  |
| Nancy Devin    | 2010-2020| 01212991    | 3     | 1    | Triple   | Up to 3 years   | 1717     | Enzalutamide (872)             | placebo (845)           | 71.3 (8.47)     | multicenter  |
Time to Prostate-Specific Antigen Progression

The results showed that abiraterone had a significant advantage over the placebo regarding TTPP in mCRPC patients (HR=0.52, 95%CI:0.45 to 0.59). Enzalutamide also resulted in a significantly longer TTPP in mCRPC patients than placebo (HR=0.19, 95% CI: 0.17-0.22) (Figure 5). The test for heterogeneity suggested that the abiraterone subgroup had moderate heterogeneity ($I^2=31\%$, $P < 0.00001$). However, the test for heterogeneity indicated that there was considerable heterogeneity in the enzalutamide subgroup ($I^2=90\%$, $P < 0.00001$). The heterogeneity stemmed from differences in observation time and the number of placebo groups between the two clinical trials.

Radiographic Progression-Free Survival

Two clinical trials each compared the effect of abiraterone or enzalutamide with that of a placebo on the rPFS of 5199 mCRPC patients. The results showed that abiraterone had a significant advantage over the placebo regarding rPFS in mCRPC patients (HR=0.64, 95% CI: 0.57-0.71; $Z=8.27$, $P < 0.0001$) (Figure 6).

Serious Adverse Event

There was no difference in safety between abiraterone and enzalutamide. (1.18, 95% CI: 1.06-1.31; 1.34, 95% CI: 1.22-1.48). The test of heterogeneity indicated that there was limited heterogeneity between the studies ($I^2=38\%$, $P=0.21$) (Figure 7).

DISCUSSION

By calculating and combining HR, our results show that both enzalutamide and abiraterone improve patients’ OS compared
FIGURE 3 | Risk of bias summary. Green circles represent a low risk of bias; red circles represent a high risk of bias; yellow circles represent an unknown risk of bias.

FIGURE 4 | Forest plots for Overall survival in studies.
with placebo. In addition, enzalutamide was more effective in improving TTPP and rPFS than abiraterone acetate and prednisone/prednisolone combination therapy. There was no significant difference in safety between the two drugs. This finding is significant because it provides substantial evidence for clinical studies in patients with metastatic prostate cancer.

Unlike the study by Wang et al (20) using OR to evaluate the effectiveness of two things, an advantage of this study is the use of combined HR to evaluate the efficacy of AR inhibitors.

Compared to the median values for OS, rPFS, and TTPP, HR takes into account both time and queue size (21–23). However, when comparing security, we used RR to compare sAE because...
we could not obtain more details of the data. In addition, since there have been a large number of meta-analyses comparing abiraterone and enzalutamide, few meta-analyses have included all relevant randomized clinical trials (RCTs) and directly combined the hazard ratio (HR) of overall survival (OS) and progression-free survival (PFS) for the two drugs. Additionally, in the absence of large RCTs for direct comparison, we used both subgroup analyses and indirect comparisons to evaluate the efficacy and safety of the drugs. Moreover, the study by Wang et al (20) contains multiple studies, but not every study has a sufficient sample size, and there may be regional bias. The clinical trials in this study have a large sample size and come from multiple regions, and the regional and ethnic bias may be smaller. Therefore, the conclusion of this study may be more convincing. First, in the subgroup analysis, there was some heterogeneity in the abiraterone group and the enzalutamide group, which may be caused by the different inclusion criteria of the experiment. In the study by Fizazi K et al (24), patients with mCRPC confirmed histologically or cytologically were eligible if they had previously received docetaxel and had received up to two previous chemotherapy treatments; however, in the study by Miller, K., et al (18), patients must not have received chemotherapy before. Second, another source of heterogeneity may be that the severity of disease and initial PSA levels were not exactly the same in the two studies. In addition, follow-up times were different between the two studies. All of these factors would result in heterogeneity within the abiraterone group. In the study by Devlin, N et al (7, 25), on the other hand, patients had to have never received cytotoxic chemotherapy; however, in the study by Armstrong, A.J et al. (19, 26, 27), patients needed to be treated with one or two advanced chemotherapy regimens, and at least one regimen had to contain docetaxel. The intragroup heterogeneity of enzalutamide may be derived from this. However, the OS heterogeneity of the two subgroups was very small, so the heterogeneity could also be derived from statistics. The results of the meta-analysis were convincing despite the heterogeneity of the multiple aggregate results. For rPFS, the study by McCool.R et al. (28) uses the method of network analysis to evaluate. However, many comparisons are made through only one experiment, and the sample size of some experiments is too small, and there may be large heterogeneity among the subgroups of the network analysis. As the number of hypothesis tests increases, the rate of false positive errors will increase substantially, even if there is no difference in effect. For the comparison of two drugs, indirect comparison is a better choice. But the conclusion is similar. Enzalutamide is better than abiraterone in improving rPFS.

In addition, we comprehensively explored the safety of abiraterone and enzalutamide and found that AR inhibitors resulted in a higher overall incidence of AE, actually significantly reduced the incidence of high-grade AE, and similar rates of AE leading to death or withdrawal. All patients in the Karin and Kurt trials were assigned to the mandatory use of prednisone to avoid or mitigate adverse events associated with related mineral corticosteroids (18, 24, 29). In contrast, in the Andrew J and Nancy trials (19, 26, 27), enzalutamide did not require the use of prednisone. The safety of abiraterone and enzalutamide appears to be acceptable and manageable, as these AEs can be managed through appropriate medical monitoring. It is important to note that heterogeneity exists between studies, which may be due to differences and heterogeneity in the treatment of abiraterone and enzalutamide. Given the limitations of the study’s reliance on published study results
rather than original individual patient data, some important baseline characteristics of patients, namely age, bone injury, visceral disease, ECOG performance status score, and GS, may also play a key role in this large heterogeneity. In addition, the incidence of high-level adverse events (sAEs) in the AR inhibitor group versus the control group was not adequately compared. To reduce potential bias, we only extracted data that strictly met our inclusion criteria, resulting in many AEs being excluded from the analysis. Therefore, in future clinical practice, AR inhibitors should be considered an effective and safe treatment option for patients with CRPC, although practitioners should pay particular attention to the AEs mentioned in our study, especially the high-level AEs. In addition, the use of uniform AE reporting standards for further in-depth data analysis is of great significance to the researchers who carried out the original study.

In the current study, it was significant and interesting for us to determine whether abiraterone acetate and enzalutamide obtained any different benefits in mCRPC through subgroup analysis. This will provide evidence for drug selection in clinical treatment. However, some questions remain unanswered: the most appropriate patient population, potential cross-resistance mechanisms, optimal sequential administration, and possible combination strategies.

There were limitations of this study, such as the limitation of the included studies to those published in English. The references of the included studies were not evaluated, which may have led to the omission of relevant studies. The use of random allocation was described, but the details of the random allocation and the allocation concealment were not included. When extracting the data, some studies did not directly report the effect size and the corresponding confidence interval; therefore, statistical methods were used to calculate the effect size based on the available information, which may have resulted in slightly different results. There are some differences between the results of direct and indirect comparisons; therefore, more prospective studies are needed to verify the findings.

CONCLUSIONS

In summary, the current evidence suggests that enzalutamide is not significantly different from abiraterone with regard to improving the OS of mCRPC patients, but it has a greater effect on TTTP and rPFS. The evidence from this study can be used when selecting a treatment option for mCRPC in clinical practice. Due to the lack of a direct comparison, the conclusions drawn from the results of the indirect comparison performed in this analysis need to be verified in high-quality prospective studies.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

HG and ZW conceived this study, conducted the searching, and drafted the manuscript. CC and BL participated in article screening and performed the statistical analysis. CC, BL, and YL checked the data. HG and ZW contributed to the design of this study and provided proposals for the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was funded by Inner Mongolia Medical University and did not receive external funding.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2020. CA Cancer J Clin (2020) 70(1):7–30. doi: 10.3322/caac.21590
2. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of Patients With Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol (2018) 73(2):178–211. doi: 10.1016/j.euro.2017.06.002
3. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality. J Clin Oncol (2007) 25(13):1765–71. doi: 10.1200/JCO.2006.08.0572
4. Zhang H, Spencer K, Burley SK, Zheng XS. Toward Improving Androgen Receptor-Targeted Therapies in Male-Dominant Hepatocellular Carcinoma. Drug Discov Today (2021) 26(6):1539–46. doi: 10.1016/j.drudis.2021.02.001
5. Izumi K, Mizokami A, Namiki M, Inoue S, Tanaka N, Yoshio Y, et al. Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer (ENABLE Study for Pca): A Study Protocol for a Multicenter Randomized Phase III Trial. BMC Cancer (2017) 17(1):677. doi: 10.1186/s12885-017-3661-2
6. Siemens DR, Klotz L, Heidenreich A, Chowdhury S, Villers A, Baron B, et al. Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients With Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. J Urol (2018) 199(1):47–54. doi: 10.1016/j.juro.2017.08.080
7. Devlin N, Herdman M, Pavesi M, Phung D, Naidee S, Beer TM, et al. Health-Related Quality of Life Effects of Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer: An in-Depth Post Hoc Analysis of EQ-5D Data From the PREVAIL Trial. Health Qual Life Outcomes (2017) 15:130. doi: 10.1186/s12955-017-0704-y
8. Yin L, Hu Q, CYP17 Inhibitors–Abiraterone, C17,20-Lyase Inhibitors and Multi-Targeting Agents. Nat Rev Urol (2014) 11(1):32–42. doi: 10.1038/nrruro.2013.274
9. Watson PA, Arora VK, Sawyers CL. Emerging Mechanisms of Resistance to Androgen Receptor Inhibitors in Prostate Cancer. Nat Rev Cancer (2015) 15(12):701–11. doi: 10.1038/nrc4016
10. Attard G, Boor M, Gurney H, Loriot Y, Andersen-Danil C, Kalleda R, et al. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. J Clin Oncol (2018) 36(25):2639–46. doi: 10.1200/JCO.2018.77.9827
11. De Laere B, Rajan P, Grönberg H, Dirix L, Lindberg J. Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-
Wei et al. Abiraterone and Enzalutamide for mCRPC

Type Metastatic Castration-Resistant Prostate Cancer. *JAMA Oncol* (2019) 5 (7):1060–2. doi: 10.1001/jamaoncol.2019.0869

12. Roviello G, Cappelletti MR, Zanotti L, Adobi A, Senti C, Bottini A, et al. Targeting the Androgenic Pathway in Elderly Patients With Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Trials. *Med (Baltimore)* (2016) 95(43):e4636. doi: 10.1097/MD.00000000000004636

13. Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, et al. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-Treated Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. *Eur Urol* (2016) 70(4):675–83. doi: 10.1016/j.euro.2016.03.017

14. Morris MJ, Heller G, Bryce AH, Armstrong AJ, Beltran H, Hahn OM, Alliance A031201: A Phase III Trial of Enzalutamide (ENZ) Versus Enzalutamide, Abiraterone, and Prednisone (ENZ/AAP) for Metastatic Castration Resistant Prostate Cancer (Mcrpc). *J Clin Oncol* (2019) 37(15_suppl):5008. doi: 10.1200/JCO.2019.37.15_suppl.5008

15. de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfling L, et al. Radium-223 and Prednisone Compared With Placebo and Prednisone on Pain Control and Skeletal-Related Events in Patients With Metastatic Castration-Resistant Prostate Cancer: Exploratory Analysis of Data From the COU-AA-301 Randomised Trial. *Lancet Oncol* (2012) 13(12):1210–7. doi: 10.1016/S1470-2045(12)70473-4

16. Phillips R. Prostate Cancer: Enzalutamide Affirms its Benefits. *Nat Rev Urol* (2014) 11(10):545. doi: 10.1038/nrurol.2014.227

17. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301 Randomised, Double-Blind, Placebo-Controlled Phase 3 Study. *Lancet Oncol* (2012) 13(10):983–92. doi: 10.1016/S1470-2045(12)70379-0

18. Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD, et al. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-Specific Antigen, and Gleason Score. *Eur Urol* (2018) 74(1):17–23. doi: 10.1016/j.euro.2017.08.004

19. Armstrong AJ, Al-Adhami M, Lin P, Parli T, Sugg J, Steinberg J, et al. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. *JAMA Oncol* (2020) 6(2):217–25. doi: 10.1001/jamaoncol.2019.4636

20. Wang X, Yang H, Hu X, Wang W, Yu X, Wang S, et al. Comparing the Clinical Efficacy and Safety of Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. *J Oncol Pharm Pract* (2021) 27(3):614–22. doi: 10.1177/1078155220929414

21. Tharyan P. The Cochrane Schizophrenia Group: Preparing, Maintaining and Disseminating the Evidence for Interventions Used for People With Schizophrenia. *Int Rev Psychiatry* (2005) 17(2):115–21. doi: 10.1080/09540260500074693

22. Volmink J, Siegfried N, Robertson K, Gülmezoglu AM. Research Synthesis and Dissemination as a Bridge to Knowledge Management: The Cochrane Collaboration. *Bull World Health Organ* (2004) 82(10):778–83.

23. Parmar MK, Torri V, Stewart L. Extracting Summary Statistics to Perform Meta-Analyses of the Published Literature for Survival Endpoints. *Stat Med* (1998) 17(24):2815–34. doi: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim10>3.0.co;2-8

24. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, et al. Effect of Abiraterone Acetate and Prednisone Compared With Placebo and Prednisone on Pain Control and Skeletal-Related Events in Patients With Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301 Randomised Trial. *Lancet Oncol* (2012) 13(12):1210–7. doi: 10.1016/S1470-2045(12)70473-4

25. Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, et al. Radiographic Progression With Nonrising PSA in Metastatic Castration-Resistant Prostate Cancer: Post Hoc Analysis of PREVAIL. *Prostate Cancer Prostato Dis* (2017) 20(2):221–7. doi: 10.1038/prcan.2016.71

26. Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, et al. Five-Year Survival Prediction and Safety Outcomes With Enzalutamide in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer From the PREVAIL Trial. *Eur Urol* (2020) 78(3):347–5. doi: 10.1016/j.euro.2020.04.061

27. Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, et al. Prognostic Association of Prostate-Specific Antigen Decline With Clinical Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide in a Randomized Clinical Trial. *Eur Urol Oncol* (2019) 2(6):677–84. doi: 10.1016/j.euo.2018.11.005

28. McCool R, Fleetwood K, Glanville J, Arber M, Goodall H, Naidoo S, et al. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naïve Patients With Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer. *Value Health* (2018) 21 (10):1259–68. doi: 10.1016/j.jval.2018.03.012

29. Fizazi K, Flåg TW, Stöckle M, Scher HI, de Bono JS, Rathkopf DE, et al. Does Gleason Score at Initial Diagnosis Predict Efficacy of Abiraterone Acetate Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer? An Analysis of Abiraterone Acetate Phase III Trials. *Ann Oncol* (2016) 27 (4):699–705. doi: 10.1093/annonc/mdv545

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wei, Chen, Li, Li and Gu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.